Anticonvulsants · Dilantin
Phenytoin (Dilantin) Side Effects and Toxicity: The CYP2C9 Link
Phenytoin controls seizures well, but it has a narrow margin between a helpful level and a toxic one. The CYP2C9 enzyme sets how fast you clear it, and slow metabolizers can tip into toxicity on a standard dose.
Phenytoin, sold as Dilantin, is a long-standing seizure medication. It works, but it is famously tricky to dose because its blood level does not rise steadily with the dose, and the gap between an effective level and a toxic one is small. The enzyme that clears phenytoin is CYP2C9, and genetic differences in CYP2C9 are a major reason some people reach toxic levels on a dose that is fine for someone else.
Why phenytoin side effects appear
Its levels rise unpredictably with dose
Phenytoin has what doctors call nonlinear, or saturable, kinetics. Once the clearance pathway is near its limit, a small dose increase can cause a large jump in blood level, which is a common path to toxicity even without any genetic difference.
Toxic levels cause distinctive signs
As phenytoin levels climb too high, people often develop unsteady walking, slurred speech, involuntary eye movements, double vision, and drowsiness. These are classic signs that the level has gone past the safe range.
Interactions shift levels in both directions
Many drugs raise or lower phenytoin levels, and phenytoin itself changes the levels of other drugs, including warfarin. Even small changes in your medication list can move you into or out of the safe range.
Your CYP2C9 genetics set the clearance speed
CYP2C9 is the main enzyme that breaks phenytoin down. Reduced function variants slow clearance, so the drug accumulates faster and toxicity becomes more likely on a standard dose.
Phenytoin levels do not rise in a straight line with the dose, so a small dose increase can cause a large jump, and that jump is bigger and faster in CYP2C9 slow metabolizers.
How your genetics can play a role
The gene that matters most for phenytoin dosing is CYP2C9, the same enzyme involved in warfarin and several NSAIDs.
| Gene | What it affects |
|---|---|
| CYP2C9 | CYP2C9 is the primary enzyme that clears phenytoin.[1] Reduced function variants, including the lower-activity star alleles, slow that clearance. FDA labeling and CYP2C9 status are used to flag people who are likely to need a lower phenytoin dose to avoid toxic levels.[2] |
If you are a CYP2C9 normal metabolizer, standard phenytoin dosing and routine level monitoring usually apply. If you are an intermediate or poor metabolizer, you clear phenytoin more slowly, so it accumulates and can reach toxic levels on a normal dose. Guidance is to significantly reduce the starting dose, or to consider a different anticonvulsant, and to be especially cautious in carriers of the lower-activity CYP2C9 star alleles.[1] Because phenytoin levels rise so unpredictably, even a modest reduction in clearance can have a large effect. Knowing your CYP2C9 status before or early in treatment helps your doctor set a safer dose and monitor it closely.[2]
Want to know what your genetics say about how you'll respond to Phenytoin?
A Gene2Rx report reads your own DNA to show how it may affect your response to Phenytoin and your other medications.
Find out todayWhen to consider pharmacogenetic testing
Pharmacogenetic testing is worth considering if you have had phenytoin toxicity or repeatedly high levels, if you are starting phenytoin and want a safer initial dose, or if you also take warfarin, which shares the CYP2C9 pathway. CYP2C9 status is one input your doctor combines with blood-level monitoring, which remains essential for phenytoin.
What you can do next
- Do not change your phenytoin dose on your own. Seizure control and toxicity both depend on careful dosing, so work with your doctor.
- Keep up with the blood-level checks your doctor orders, since they are the main way to keep phenytoin in the safe range.
- Report early toxicity signs like unsteadiness, slurred speech, or double vision promptly.
- Consider pharmacogenetic testing to learn whether your CYP2C9 genetics make you more likely to accumulate phenytoin.
Related medications
Related guides
- Celecoxib (Celebrex) Side Effects: The CYP2C9 Connection
- How Is Ibuprofen Metabolized? CYP2C9, Side Effects, and Your Genes
- Meloxicam (Mobic) Side Effects: How CYP2C9 Raises the Risk
- 23andMe Drug Response: What You'll Actually See in a Report From Your Data
- 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
- AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
Frequently asked questions
Why does my phenytoin level get too high so easily?
Phenytoin has nonlinear kinetics, so its level can jump sharply with a small dose increase. If you are a CYP2C9 intermediate or poor metabolizer, you clear it more slowly, which makes those jumps bigger and toxicity more likely. This is why level monitoring is so important with phenytoin.
Is Dilantin the same as phenytoin?
Yes. Dilantin is a brand name for phenytoin, so the same CYP2C9 considerations apply across brand and generic versions.
Does a genetic test replace phenytoin blood-level monitoring?
No. A CYP2C9 result helps explain why your levels behave the way they do and can guide a safer starting dose, but phenytoin still requires ongoing blood-level checks because so many factors affect it. The two work together rather than one replacing the other.
References
- U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling (2024). fda.gov
- Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines. cpicpgx.org
Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medication. Never stop or change a medication without medical supervision.